Plain-English translation of NCT06486792 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Stroke research guide →Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
After a stroke with no clear cause, doctors suspect you might have an irregular heartbeat (atrial fibrillation) that hasn't been detected yet. This trial is comparing two treatment approaches: starting you on anticoagulation (a blood thinner medication like , rivaroxaban, dabigatran, or a vitamin K antagonist) versus starting you on . The goal is to figure out which treatment better prevents a second stroke while doctors search for the irregular heartbeat over the next several months.
When patients have a stroke from an unknown cause, doctors strongly suspect a hidden irregular heartbeat is to blame—but it takes time to find it. While searching, the question is: should doctors give the medication right away (which reduces stroke risk by 80% if the irregular heartbeat is real), or wait and use instead (which only reduces risk by 20%)? This trial is needed because no one has actually tested whether the medication is truly better and safer than in this specific situation.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to take either a blood thinner medication or daily. While taking your assigned medication, you will wear a heart monitor or have regular ECG tests over the next 6–12 months so doctors can search for an irregular heartbeat. If an irregular heartbeat is found, you'll continue the blood thinner; if the search is negative after 6–12 months, you'll switch to for long-term prevention. You'll attend follow-up visits so doctors can monitor your progress and watch for any side effects.
AI-generated summary from trial data · Jun 22, 2026 · Not medical advice
France